Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after first-line systemic therapy. PATIENTS AND METHODS: In this open-label phase III clinical study, patients with advanced or metastatic ESCC, whose...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A., Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462531/
https://www.ncbi.nlm.nih.gov/pubmed/35442766
http://dx.doi.org/10.1200/JCO.21.01926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462531/
https://www.ncbi.nlm.nih.gov/pubmed/35442766
http://dx.doi.org/10.1200/JCO.21.01926

Ejemplares similares